NCT06143553
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
At risk: Primary completion moved at least 2 years later.
See at-risk trials from Shanghai Yizhong Pharmaceutical Co., Ltd.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 2025 to Dec 31, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 42 words
- Trial status changed: Unknown → Recruiting
- Study completion pushed from Dec 2025 to Jun 30, 2028
- Secondary endpoints: details revised at 1 of 4 entries
- Minor Changed Registry marked status Unknown; last known: Recruiting
Notable Eligibility criteria expanded, about 5 wordsv2 Show 5 more changesShow less
- Trial status: Recruiting to Unknown
- Primary and study completion dates: Jul 2025 to Dec 2025
- Start date: Oct 30, 2023 to Sep 25, 2023
- Secondary endpoints: 5 to 4
- Study title revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Control Group:The Doctor chooses the treatment(TPC):Eribulin Mesilate injection;Capecitabine Tablets;Gemcitabine Hydrochloride for Injection;Vinorelbine Tartrate Injection;Paclitaxel (albumin-bound). Eribulin Mesilate injection:on days 1 and 8 of the 21-day cycle, 1.4 mg/m2 , intravenous administration; Capecitabine Tablets: On days 1 to 14 of the 21-day cycle, 1000-1250mg/m2,oral administration, twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2); Gemcitabine Hydrochloride for Injection: On days 1, 8 and 15 of the 28-day cycle, 800-1200mg/m2, intravenous administration; Vinorelbine Tartrate Injection: Every first day of the week, 25mg/m2,intravenous administration; Paclitaxel (albumin-bound): On day 1 of the 21-day cycle, 260mg/m2,intravenous administration for more than 30 minutes. Three weeks constituted one course of treatment.
Drugs: Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)
Sites
3 sites in 1 country